Related Experiment Videos
Summary
Tranexamic acid significantly reduces secondary hemorrhage risk in traumatic hyphaema patients, with only a 0.32% occurrence. This antifibrinolytic drug offers a safe and effective treatment option for eye trauma.
Area of Science:
- Ophthalmology
- Trauma Care
- Pharmacology
Background:
- Traumatic hyphaema can lead to secondary hemorrhage, a significant complication.
- Antifibrinolytic agents are used to manage bleeding disorders.
Purpose of the Study:
- To evaluate the efficacy of tranexamic acid in preventing secondary hemorrhage after traumatic hyphaema.
- To investigate the relationship between serum activator inhibitor levels and corneal thickness in untreated patients.
Main Methods:
- Retrospective analysis of 310 patients treated with tranexamic acid for traumatic hyphaema.
- Daily monitoring of serum activator inhibitor and central corneal thickness in four untreated patients.
Main Results:
- A low rate of secondary hemorrhage (0.32%) was observed in patients treated with tranexamic acid.
- Serum activator inhibitor levels increased in the first five days post-trauma and decreased by the sixth day in untreated patients.
Conclusions:
- Tranexamic acid is highly effective in preventing secondary hemorrhage in traumatic hyphaema.
- Further research is warranted to understand the role of activator inhibitor and corneal changes in hyphaema recovery.